PD-L1 Monoclonal Antibody(Capture) (AN001380P)
For research use only.
| Verified Samples | Verified Samples in ELISA: Recombinant Human PD-L1 protein, Human serum, Human plasma |
| Dilution | ELISA Capture 2-8 μg/mL |
| Isotype | Mouse IgG1 |
| Host | Mouse |
| Reactivity | Human |
| Applications | ELISA Capture |
| Clonality | Monoclonal |
| Immunogen | Recombinant Human PD-L1 L1 protein expressed by Mammalian |
| Abbre | PD-L1 |
| Synonyms | CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, PD-L1, Programmed ceLL death 1 Ligand 1, B7 homoLog 1, PDCD1 Ligand 1, Programmed death Ligand 1, hPD-L1 |
| Swissprot | |
| Concentration | 1 mg/mL |
| Buffer | Phosphate buffered solution, pH 7.2, containing 0.05% proclin 300. |
| Purification Method | Protein A/G Purification |
| Research Areas | Immunology, Cancer |
| Clone No. | 9B7 |
| Conjugation | Unconjugated |
| Storage | Store at 4°C valid for 12 months or -20°C valid for long term storage, avoid freeze / thaw cycles. |
| Shipping | The product is shipped with ice pack, upon receipt, store it immediately at the temperature recommended. |
| background | Plays a critical role in induction and maintenance of immune tolerance to self.As a ligand for the inhibitory receptor PDCD1/PD-1,modulates the activation threshold of T-cells and limits T-cell effector response.Through a yet unknown activating receptor,may costimulate T-cell subsets that predominantly produce interleukin-10 (Il10).Can also act as a transcription coactivator: in response to hypoxia,translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC,leading to pyroptosis.The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system,thereby facilitating tumor survival.The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTls) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response,providing a rationale for cancer immunotherapy. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
